Real Time Microfluidic Blood Counting System for PET and SPECT Preclinical Pharmacokinetic Studies

Laurence Convert1,2,3, Réjean Lebel1, Suzanne Gascon1, Réjean Fontaine3, Jean-François Pratte3, Paul Charette2,3, Vincent Aimez2,3, Roger Lecomte1

1Sherbrooke Molecular Imaging Centre of CRCHUS and Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke, Sherbrooke, QC, Canada
2Laboratoire Nanotechnologies Nanosystèmes (LN2) - CNRS UMI-3463, Université de Sherbrooke, Sherbrooke, QC, Canada
3Institut Interdisciplinaire d’Innovation Technologique (3IT), Université de Sherbrooke, Sherbrooke, QC, Canada

Corresponding author and request for reprints:
Roger Lecomte, PhD
Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke
3001, 12th Avenue N., CRCHUS #1977, Sherbrooke, QC, Canada J1H5N4
Roger.Lecomte@USherbrooke.ca
Phone: +1(819)821-8000 #14608

First Author:
Laurence Convert, PhD, postdoctoral fellow
Parc Innovation, Pavillon P2, Université de Sherbrooke
3000 Blvd Université, Sherbrooke, QC, Canada, J1K0A5
Laurence.Convert@USherbrooke.ca
Phone: +1(819)821-8000 #65895

Word count: 5,981

This work was supported by the Canadian Institutes of Health Research (CIHR) grant #MOP-86717 and NanoQuébec. The Research Centre of CHUS (CRCHUS) hosting the Sherbrooke Molecular Imaging Centre is a FRQS-funded research organization.

Running title: Microfluidic blood counting system
ABSTRACT

Small animal nuclear imaging modalities have become essential tools in the development process of new drugs, diagnostic procedures and therapies. Quantification of metabolic or physiologic parameters is based on pharmacokinetic modelling of radiotracer biodistribution, which requires the blood input function in addition to tissue images. Such measurements are challenging in small animals because of their small blood volume. In this work, we propose a microfluidic counting system to monitor rodent blood radioactivity in real time, with high efficiency and small detection volume (≈1 µL). Methods. A microfluidic channel is built directly above unpackaged p-i-n photodiodes to detect beta particles with maximum efficiency. The device is embedded in a compact system comprising dedicated electronics, shielding, and pumping unit controlled by custom firmware to enable measurements next to small animal scanners. Data corrections required to use the input function in pharmacokinetic models were established using calibrated solutions of the most common Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) radiotracers. Sensitivity, dead time, propagation delay, dispersion, background sensitivity, and the effect of sample temperature were characterized. The system was tested for pharmacokinetic studies in mice by quantifying myocardial perfusion and oxygen consumption with $^{11}$C-acetate (PET) and by measuring the arterial input function using $^{99m}$TcO$_4^-$ (SPECT). Results. Sensitivity for PET isotopes reached 20-47%, a 2- to 10-fold improvement relative to conventional catheter-based geometries. Furthermore, the system detected $^{99m}$Tc-based SPECT tracers with an efficiency of 4%, an outcome not possible through a catheter. Correction for dead time was found to be unnecessary for small animal experiments, while propagation delay and dispersion within the microfluidic channel were accurately corrected. Background activity and sample temperature were shown to have no influence on measurements. Finally, the system was successfully used in animal studies. Conclusion. A fully operational microfluidic blood counting system for preclinical pharmacokinetic studies was developed. Microfluidics enabled reliable and high efficiency measurement of the blood concentration of most common PET and SPECT radiotracers with high temporal resolution in very small blood volume.
Keywords: Pharmacokinetic studies; Microfluidic; Arterial input function; Small animal PET; Small animal SPECT.
INTRODUCTION

Radionuclide-based molecular imaging using PET and SPECT is a leading diagnostic tool in oncology, cardiology, and neurology (1). In research applications, small animal models are needed to facilitate the development of new drugs, radiotracers, and therapies that can eventually be translated to humans (2). Quantification of metabolic or physiologic disorders using radiotracer pharmacokinetic models requires dynamic blood analysis in addition to tissue imaging data (3). Whole-blood radioactivity as a function of time, the so-called arterial input function (AIF), can be extracted from PET images (4,5), using an intravascular beta microprobe (6,7) or an external blood counter connected to an artery via a catheter (8–10). For accurate quantification, the measured whole-blood AIF must be corrected for known plasmatic and metabolite fractions. For new radiotracers, such parameters are not yet established and blood samples have to be drawn and analysed. However, repetitive manual blood sampling is difficult, time-consuming and can affect the animal homeostasis, especially in mice (~1.4 mL total blood volume).

Lab-on-a-chip devices are miniature analysis platforms based on microelectronic fabrication principles that integrate one or several laboratory functions (11). They incorporate micron-scale fluidic channels that can perform several operations like plasma separation, radiation detection, and chemical analysis. Thus, microfluidics technology is an attractive solution to provide full characterisation of new radiotracers in small-animal studies. In this work, we present one building block of such an integrated microfluidic system for real-time blood radioactivity monitoring.

PET radiotracers emit positrons (β⁺), with $E_{\text{βmax}}$ ranging typically from 0.6 to 1.9 MeV, that rapidly annihilate producing two 511 keV annihilation photons. Most SPECT radiotracers emit β⁻ and gamma-rays (60 to 250 keV) typically accompanied by Auger or conversion electrons (CE, <150 keV). Thus both PET and SPECT radiotracer concentration in blood can be monitored either by charged particle (β, Auger or CE) or photon (gamma or annihilation) detection. High-energy photon detection requires high-density crystals, 1-2 cm thick, that are
not appropriate for microsystem integration. Charged particle detection is therefore preferred as it can be performed in a silicon wafer, the traditional substrate for microfluidic chips (12).

Charged-particle detection for blood radioactivity monitoring in pharmacokinetic studies faces several challenges: (1) Charged particles are stopped within a few micrometers to a millimeter in matter depending on their energy; CE, Auger, and a significant part of the polyenergetic β particles are severely attenuated at the interface between sample and detector; (2) Radiotracer concentration in rodents blood is typically <100 Bq/µL after tissue uptake; (3) In mice, only a few hundred µL at most are available for analysis over 10-45 min, hence detection volume must be kept as small as possible, around 1 µL, at any given time during measurement; (4) A temporal resolution better than 4 s has been suggested as a pre-requisite for accurate estimation of pharmacokinetic parameters (13). The detector must be able to measure a few tens events/second at a minimum to procure a statistically significant signal. Hence, detection efficiency must be maximized and the interface thickness between sample and detector minimized.

Examples of microfluidic systems for related applications were previously reported. Two microfluidic chips were developed for micro-blood sampling in PET imaging (14,15), but no radiation detector was integrated. Samples had to be measured off-line in a well-counter, which can be limiting for short half-life radioisotopes, i.e., 15O (2 min), 13N (10 min) or 11C (20 min). Radiation detectors were used with microfluidic chips for DNA detection (16), protein adsorption (17), radiosynthesis monitoring (18), cell imaging (19) and protein crystallography (20), but with off-chip detectors. An early integrated chip design dedicated to charged particle detection was proposed in the late 1990s for DNA detection (21), but the authors opted for fluorescence detection in the actual integration (22). More recently, a polydimethylsiloxane microfluidic chip was coupled to a position-sensitive avalanche-photodiode detector for cell imaging (23), but the interface thickness between sample and detector limited the sensitivity for PET tracers and did not allow the detection of low-energy CE such as the ones emitted by 99mTc.
In previous work, our group built a microfluidic channel directly above an unpackaged \textit{p-i-n} silicon photodiode array, eliminating all unnecessary interfaces between blood and the photodiode detection layer to overcome these limitations (24,25). We also proposed a method to improve the blood compatibility of the microchannel polymer building material (26). The microfluidic geometry was optimized, the fabrication process detailed, and a preliminary characterisation of the microfluidic chip was performed (27). In the present work, we describe a prototype blood-counting system comprising the microfluidic chip together with dedicated electronics, software, and pumping unit. Data corrections required to use the measured AIF in pharmacokinetic models are described and fully characterized for the most common PET and SPECT radiotracers. Finally, the system was used for the measurement of myocardial perfusion and oxygen consumption in mice using the PET tracer $^{11}$C-acetate and to determine the AIF of the SPECT tracer $^{99m}$TcO$_4^-$ in mice.

**MATERIALS AND METHODS**

**System Overview**

The proposed microfluidic blood counting system is based on direct beta or electron detection within a microchannel built above unpackaged \textit{p-i-n} photodiodes. It consists of two separate hardware modules, a detection unit enclosed in a compact radiation shield linked to a peristaltic pump and a control unit (Fig. 1) (see Supplemental Section 1 for detailed description).

**Microfluidic Detector**

The microfluidic chips were built with a rectangular microchannel forming a quasi-2D source and, therefore, achieving quasi-perfect geometrical detection efficiency (Fig. 2A). Furthermore, the microfluidic chips were designed to leave only a few micrometers between the sample and the detector, drastically decreasing particle energy loss (27) before reaching the detection region (~2 keV) compared to a conventional design built with a catheter (e.g., polyethylene tubing, Intramedic PE50 or PE10, Becton Dickinson, USA) (~200 keV).
The channel was microfabricated over a 44×22 mm² die containing a linear array of eight 2×2 mm² silicon p-i-n photodiodes from Excelitas Technologies (Vaudreuil, Canada). The detailed fabrication process was reported elsewhere (27) and is briefly summarized in Supplemental Section 1. The resulting microfluidic chips had a 37×1125 µm² cross section and 16 mm length for a detection volume of 0.66 µL.

As a first validation of the microfluidic blood counting system, energy spectra were recorded at the shaping amplifier output and confirmed the validity of the measurement (25). Briefly, low-energy gammas and X-rays from 241Am and 133Ba sources provided a calibration factor of 4.38 mV/keV and a noise level of 25 keV. Liquid sources showed a characteristic continuous spectrum for a β emitter (18F) and a peak for a CE emitter (99mTc).

**Catheter-Based Detector**

In order to characterize the gain in performance attributable to the microfluidics design, comparative measurements were conducted with a commercially packaged p-i-n photodiode (S3588-08, 3×30 mm² with ~500 µm epoxy protection layer, Hamamatsu Corporation, Japan) and a catheter bonded to its surface as pictured in Figure 2B.

**Data Corrections**

To be used as an AIF in pharmacokinetic models, the data recorded by the microfluidic blood counting system must be corrected for radionuclide decay time, detector sensitivity, radioactivity dispersion and propagation delay between the cannulation point and the detector. The system was also assessed for dead time, sensitivity to background radioactivity, and influence of sample temperature (see Supplemental Section 2 for details). For all experiments, the detection threshold was adjusted to record 5 cps background count rate before injecting the radioactivity (8) and all recorded count rates were decay-corrected by software referred to the acquisition start.

*Sensitivity* relates the measured count rate to the actual radioactive concentration in the detection volume. For direct beta detectors, the sensitivity is dependent on the incident particle energy and specific detection geometry, therefore it has to be characterized for each
radionuclide. The microfluidic chip and a piece of PE50 or PE10 bonded to the catheter-based
detector were consecutively injected with 10 kBq/µL solutions of four common PET
radioisotopes (\(^{18}\text{F}, ^{11}\text{C}, ^{64}\text{Cu}, ^{68}\text{Ga}\) ) and a 40 kBq/µL solution of the SPECT isotope \(^{99m}\text{Tc}\). The
detection threshold was adjusted and data acquisition started for two minutes. The average
count rate, \(m\) (cps), corrected for radioactive decay, was used to calculate the device absolute
detection efficiency \(\eta\) (%) for each radioisotope, following:

\[ \eta = \frac{m}{C \times V}, \quad \text{Eq. 1} \]

where \(C\) (Bq/µL) is the calibrated solution concentration and \(V\) (µL) is the device detection
volume. Minimum and maximum detectable activities (Bq/µL), were then computed as:

\[ A_{\text{min}} = \frac{2.706+4.653\sqrt{b}}{\eta \times V}, \quad \text{Eq. 2} \]
\[ A_{\text{max}} = \frac{N_{\text{max}}}{\eta \times V}, \quad \text{Eq. 3} \]

where \(b = 5\) cps is the background count rate and \(N_{\text{max}} = 65,535\) cps is the maximum count rate
allowed by the control unit 16-bit counter. Equation (2), derived from the frequently quoted
“Currie equation”, can be interpreted as the minimum activity ensuring a false-positive readout
less than 5% of the time (28).

Propagation Delay. The dead volume between the cannulation point and the detector causes
a propagation delay. For typical mouse studies, the fluid path consists of a 20-cm-long PE10
tubing (12 µL) from the animal to the detection unit entry and an 8-cm-long PE10 tubing (5 µL)
inside the detection unit. The fluidic junctions to tubing have no dead volume. Hence, the total
dead volume is 17 µL and the propagation delay is 35 s @ 30 µL/min and 74 s @ 14 µL/min.

Dispersion effects produce distortion of transient radioactive concentrations in catheters,
and may have a great impact on pharmacokinetic parameters, especially when estimating fast
blood-tissue exchange parameters, such as in blood flow measurements (29,30). Dispersion
depends on several factors, including catheter internal diameter, withdrawal rate, and distance
between the animal and detector. Fluidic junctions between the catheter and the microfluidic
chip may also contribute to dispersion. The correction procedure for dispersion is based on a fit
of the measured AIF using a bi-exponential model (see Supplemental Section 3 for a detailed description).

To validate the method, an AIF measurement was simulated with radioactive water, corrected for dispersion and compared to manual samples. A reservoir was filled with 2 mL of cold water and placed on an agitating plate. The reservoir was sampled at 14 or 30 µL/min through a 20-cm-long PE10 catheter connected to the microfluidic counting system. \(^{18}\)F-FDG was injected 30 s after starting the acquisition (21.6 MBq, 0.3 mL @ 0.9 mL/min using a syringe pump). A slow injection of cold water was started at the same time to simulate the tracer clearance (10 mL @ 7 mL/min using another syringe pump). Manual samples (25 µL) were withdrawn using a micropipette every 10 s for 90 s, then every 15 s for 30 s and every 2 min up to the end of the 10-min acquisition. Each sample was weighted to assess the exact volume. Samples radioactivity was then measured using a \(\gamma\)-well counter (Cobra II Auto-gamma; Canberra-Packard, USA). Both AIF obtained from manual samples and from the blood counter were corrected for radioactive decay and for the sensitivity of each counter. The latter was further corrected for propagation delay. A third AIF was obtained by correcting the AIF from the blood counter for dispersion as indicated above. To assess the efficiency of this correction, the three AIFs were compared using a repeated-measures one-way analysis of variance test with the Greenhouse-Geisser correction and Dunnett’s multiple comparison using the manual samples as a reference. The curves were considered significantly different for \(p \leq 0.05\).

**Animal Studies**

**Animal Preparation.** Animal experiments were performed in accordance with the recommendations of the in-house Ethics Committee for Animal Experiments and the Canadian Council on Animal Care. BALB/c and C57BL/6 mice had free access to food and water before the experiment. The animals were anesthetized with isoflurane (2% + 1.5 L/min \(O_2\)) and cannulated in the caudal vein for injection and in the carotid artery for blood withdrawal (20-cm-long PE10 catheter pre-filled with heparinized saline, 0.9%, 50 U/mL). The animal
temperature was regulated and the heart beat and breathing were monitored to ensure that physiological conditions were maintained stable during the experiment.

**PET Pharmacokinetic Study.** A study was performed to investigate the measurement of myocardial blood flow and oxygen consumption in a mouse with $^{11}$C-acetate using the microfluidic blood counting system. This study yielded an AIF from PET images in addition to the AIF measured by the blood counter. A cannulated BALB/c mouse (28 g) was placed in a LabPET4 scanner (31) (Gamma Medica Inc., USA) with a transaxial and axial field of view of 11 cm and 3.75 cm, respectively, and a nearly isotropic resolution of 1.35 mm. The heart was centered in the field-of-view and the withdrawing cannula was connected to the microfluidic blood counting system. To minimize the cannula length and keep it straight, the blood counter was placed at the rear of the scanner. The discriminator threshold of the blood counter was then adjusted and the pump speed was set to 14 µL/min. Both the PET and counter acquisitions were started in synchronization 30 s before injecting 40.2 MBq of $^{11}$C-acetate (0.1 mL @ 0.2 mL/min) in the animal. The blood drawing rate was lowered to 10 µL/min after 4 min and kept unchanged up to the end of the 20.5 min acquisition. After the experiment, a cylindrical mouse phantom (1.2 kBq/µL, 26.6 mL) was scanned to calibrate the PET images.

**Technetium AIF Measurement.** A second mouse study was performed to validate the AIF measurement using the SPECT radiotracer $^{99m}$TcO$_4^-$. A C57BL/6 mouse (28 g) was anesthetized and cannulated as described above. A 45-min acquisition was then started on the microfluidic blood counting system (14 µL/min) and 88 MBq (0.15 mL @ 0.3 mL/min) of $^{99m}$TcO$_4^-$ was injected 1 min later. After 5 min, the drawing rate was lowered to 10 µL/min for the remaining time. For this experiment, the input of the blood counter was switched back to non-radioactive saline after 43 min.

**Data Analysis and Corrections.** AIFs measured with the blood counter were corrected for decay time, sensitivity, propagation delay and dispersion. The measured data, recorded every second, were also smoothed using a 10-second moving average filter to reduce statistical noise caused by the random nature of radioactive decay. PET images were reconstructed using a maximum-likelihood estimator algorithm with 15 iterations and using the dynamic sequence.
1×30 (pre-injection), 12×5, 8×30, 2×150 and 2×300 s (25 frames). Attenuation and scatter corrections were not applied. Myocardium time activity curves (mTAC) and image-derived input functions (IDIF) were obtained by manually drawing regions-of-interest (ROIs) on the myocardium and left ventricle, respectively, in the summed frames of the interval from 2 to 3 min. IDIF was corrected for spill-in effects assuming a ROI volume of 2.5 mm³ and both mTAC and IDIF were corrected for partial volume considering a ROI average diameter of 2.5 mm (32). A three-compartment kinetic model was used for computing myocardial blood flow ($K_1$) and oxygen consumption ($k_2$) using the equations described in Supplemental Section 4. For validation, we performed a comparison between $K_1$ and $k_2$ parameters estimated using IDIF or AIF obtained from the microfluidic blood counting system.

RESULTS

Data Corrections

* Sensitivity. Sensitivity parameters computed using Equations 1-3 are summarized in Table 1 for different isotopes measured by microfluidic and catheter-based detectors. Absolute detection sensitivities ($\eta$) of the microfluidic detector for PET isotopes ranged from 20% to 47%, a 2- to 10-fold gain relative to the conventional catheter-based configurations. Minimum detectable activities ($A_{\text{min}}$) of PET isotopes ranged from 42 to 100 Bq/µL for Chip 1, while they ranged from 33 to 254 Bq/µL for PE10 and from 10 to 93 Bq/µL for PE50. These sensitivities are suitable for most pharmacokinetic PET studies in small animals. PE50 yields lower $A_{\text{min}}$, but has a larger detection volume requiring more blood. For comparison purposes, estimates for “Chip 2” with a larger detection volume (37×1250 µm² cross section, 31.5 mm detection length) were added in Table 1, assuming the same $\eta$ as Chip 1. The resulting detection volume is 1.46 µL, yielding $A_{\text{min}}$ ranging from 19 to 45 Bq/µL, up to twice lower than that obtained with PE50 having a detection volume of 7.93 µL. Finally, the microfluidic blood counting system was able to record an AIF with $^{99m}$Tc ($A_{\text{min}} = 238$ to 527 Bq/µL), which was not possible with the conventional catheter-based geometry ($A_{\text{min}} > 1$ kBq/µL). Maximum detectable activity ranged from 50 to 1267 kBq/µL for PET isotopes and was above 500 kBq/µL for $^{99m}$Tc.
Dispersion. The AIF measured from manual samples and from the microfluidic blood counting system with and without the correction for dispersion are shown in Figure 3. The analysis of variance test showed that the blood counter curve corrected for dispersion is not statistically different from manual samples ($p = 0.03$), while it is without the correction ($p = 0.74$). The resulting fitted dispersion time constant $\tau_{\text{disp}}$ was 5.4 s and 2.8 s at 14 µL/min and 30 µL/min withdrawal rate, respectively.

Animal Studies

PET Pharmacokinetic Study. Typical IDIF and mTAC obtained from PET images and the corrected AIF obtained from the microfluidic blood counting system are illustrated in Figures 4A and B, together with the PET images of the mouse heart for the 2-3 min time frame and the ROIs used to compute the mTAC and IDIF (Fig. 4C). The resulting myocardial blood flow and oxygen consumption indexes given by the rate constants $K_1$ and $k_2$ are 3.4 min$^{-1}$ and 0.9 min$^{-1}$, respectively, using the IDIF as the blood curve in the kinetic model. These values are 3.5 min$^{-1}$ and 0.7 min$^{-1}$ using the AIF from the microfluidic blood counting system corrected for dispersion. These values are in good agreement with values of $K_1 = 3.5\pm1.0$ min$^{-1}$ and $k_2 = 1.3\pm0.5$ min$^{-1}$ obtained in rats with a similar protocol (32). The dispersion time constant fitted by the dispersion correction model was $\tau_{\text{disp}} = 9.4$ s. As expected from fluid viscosities, the dispersion is higher in this experiment performed with blood than in the previous one performed with water for an identical setup.

Technetium AIF Measurement. An AIF obtained with the microfluidic blood counter following $^{99m}$Tc injection in a mouse is shown in Figure 5 with and without correction for dispersion. This experiment confirms the ability of the microfluidic system to measure AIF with the SPECT isotope $^{99m}$Tc emitting only low-energy conversion electrons. It also confirmed the system’s ability to perform data acquisition up to 40 min without blood clotting and without any significant tracer adsorption to the microfluidic chip walls, as the count rate returned to background level when non-radioactive saline was injected in the microfluidic counter.

DISCUSSION
Microfluidic Blood Counting System

This work describes a microfluidic blood counting system to monitor blood radioactivity from PET and SPECT radiotracers with high efficiency and high temporal resolution in a very small blood volume. The technology is compatible with integration of other on-chip functionalities such as plasma separation from whole-blood, and plasma sampling and analysis as a function of time to increase the throughput of new radiotracers development.

Invasiveness of external AIF measurement is often mentioned as a drawback that makes follow-up studies difficult, especially when the animal is cannulated in the carotid artery as in the studies presented in this work. Blood withdrawal is however necessary when chemical analysis of plasma samples is required to quantify metabolites of new radiotracers. Less invasive cannulation points such as tail artery can then be adopted in conjunction with a microfluidic blood counting system (33).

Sensitivity. The proposed microfluidic blood counting system shows very high absolute detection efficiency for PET tracers, especially for isotopes with the highest $E_{\text{fmax}}$, i.e., $^{11}$C and $^{68}$Ga. The achieved efficiencies, respectively 47% and 43%, are almost ideal considering that the emission is random and that the detector covers only one side of the microchannel.

The $\beta$ emitting isotopes with lower energy, $^{18}$F and $^{64}$Cu, have slightly reduced detection efficiency because a larger fraction of the particles do not reach the detector or produce a signal below the noise threshold. The detection efficiency of $^{64}$Cu is also affected by a $\beta$ emission probability of only 56%. Owing to the very thin interface thickness between the sample and detector, as well as to the more efficient detection geometry, the loss of detection efficiency for low-energy isotopes is however much less significant with the microfluidic system, improving from more than a five-fold drop between $^{11}$C and $^{64}$Cu for catheter-based detectors to only slightly more than a two-fold reduction for the microfluidic detector.

The gain in sensitivity achieved with the current microfluidic device would still not be sufficient to be applicable for use in human studies, considering typical peak and equilibrium blood tracer concentrations of 74 and ~7 Bq/µL, respectively. However, microfluidic devices
with larger detection volumes (see Table 1, Chip 2) and optimized detection geometry can readily be designed to achieve the required sensitivity.

**Dispersion correction.** Kinetic parameters are estimated using AIF and TAC as inputs. However, dispersion of the radioactive bolus inside the catheter of an external blood counter distorts the AIF relative to the sampling site and leads to error in kinetic parameters. For example, Votaw et al. (34) measured a 0.3% error in cerebral blood flow estimated with H\(^{15}\)O for a dispersion of 1.3 s. This error rises to 33% for a dispersion of 10 s. Dispersion can be reduced by minimizing the animal-to-detector distance, by decreasing the cannula internal diameter and by maximizing the withdrawal rate. Unfortunately, dispersion is always significant in typical experiments with mice, mainly because of the limited withdrawal rate. If the injection site is far from the sampling site, dispersion inside the animal can also affect the measured AIF. Such dispersion should however be taken into account by the bi-exponential model used for correction (35).

The method implemented here to correct for dispersion yields satisfactory results. Compared to other methods reported in the literature, fitting of the measured AIF has the advantage of requiring no previous parameters estimation. However, initial parameters, especially the injection time, must have been well recorded to obtain reproducible results. In the present study (see Supplemental Section 3), two consecutive fits were made, the first one to have a good estimation of input parameters and the second for more accurate fitting of the tracer *in vivo* kinetics.

In one validation study, the experimentally simulated AIF was compared to manual sampling. Even if manual sampling is considered as the gold standard for AIF measurements, its temporal resolution is limited and may induce distortion in the AIF too (33). Another common reference for non-dispersed AIF is the IDIF extracted from a ROI in PET images. However, the temporal resolution in dynamic image series can also be limited and such measurements require further partial volume and spill-in corrections that may as well introduce additional errors.
Animal studies

The proposed microfluidic blood counting system was successfully used with rats (27) and mice in this work after injection of PET and SPECT tracers. The counter-derived AIF was successfully compared to manual samples in a phantom experiment. Direct comparison of the AIF to IDIF in the present PET study with mice was not straightforward: on one hand, AIF must be corrected for propagation delay and dispersion, and on the other hand, IDIF is affected by partial volume and myocardium activity spilling in the left ventricle. Although the rising edges were very similar, some contamination was visible on the falling edge of the IDIF (see Fig. 4), even when applying spill-in correction. Moreover, the sampling period for IDIF is limited to ~5 s in practice, which induces undesirable smoothing of the peak corresponding to the bolus injection and reduces its maximum. All these factors influence the reliability and accuracy of pharmacokinetic parameters calculated from IDIF (4,5). Also, only whole-blood radioactivity can be estimated from IDIF, limiting its use to known radiotracers. In all those respects, the microfluidic blood counting system will be an attractive alternative to IDIF and manual sampling for AIF measurements.

CONCLUSION

A blood counting system, based on the detection of beta particles in a microfluidic chip, was developed to monitor the radioactivity in rodent’s blood in real time with high efficiency using a very small blood volume. The system comprises dedicated electronics, software and pumping unit for stand-alone use in PET and SPECT studies. Sensitive measurements can be performed with high temporal resolution for pharmacokinetic studies in mice. Furthermore, the microfluidic design enables the detection of $^{99m}$Tc-based SPECT tracers, which is not possible with catheter-based beta detection systems. Experiments showed that the system is insensitive to background radioactivity and blood temperature and that no dead time correction is required. Simple and robust corrections were successfully applied for delay and dispersion. Microfluidics provides a reliable and attractive solution for blood radioactivity measurement in pharmacokinetic studies with small animals.
ACKNOWLEDGMENTS

The authors would like to thank Dr. Henri Dautet of Excelitas Technologies for supplying the p-i-n photodiode wafers, Véronique Dumulon-Perreault and Mélanie Archambault from the Sherbrooke Molecular Imaging Centre for support with animal experiments, Sylvain Lauzier and Jean-Nicolas Mélançon-Emond from the Department of Electrical and Computer Engineering for help with the electronic boards and the staff of the Nanofabrication and Nanocharacterisation Research Center (CRN2) of Université de Sherbrooke for microfabrication support.
REFERENCES


FIGURE LEGENDS

FIGURE 1. Schematic view of the microfluidic blood counting system.
FIGURE 2. 3D and cross-section views of the microfluidic chip (A) and of a catheter-based geometry for beta detection (B) (not to scale).
FIGURE 3. (A) AIF simulated by injecting $^{18}$F-FDG (21.6 MBq, 0.3 mL @ 0.9 mL/min) in a reservoir while flushing with cold water (10 mL @ 7 mL/min). AIF were obtained manually (micropipette) and with the microfluidic blood counting system (14 µL/min withdrawal) to validate the dispersion correction. (B) Detailed view of the bolus region.
FIGURE 4. (A) AIF, IDIF and mTAC obtained after bolus injection of $^{11}$C-acetate (40.2 MBq in 0.1 mL @ 0.2 mL/min, no flush) in a 28 g BALB/c mouse. AIF was obtained at 14 µL/min withdrawal rate for 4 min, then at 10 µL/min for the remaining of the experiment. (B) Detailed view of the bolus region. (C) IDIF and mTAC were calculated from ROI on left ventricle and myocardium, respectively.
FIGURE 5. AIF measured with the microfluidic blood counter after bolus injection of $^{99m}$TcO$_4^-$ (88 MBq in 0.15 mL @ 0.3 mL/min, no flush) in a 28 g C57BL/6 mouse. Withdrawal rate was reduced after 5 min. Measured data were corrected for radioactive decay and smoothed to decrease statistical error (moving average, 10 s).
TABLE 1. Absolute detection efficiency and detection limit for microfluidic and catheter-based detectors. Detection volume is indicated in brackets for each device. Data for microfluidic Chip 2 were computed.

<table>
<thead>
<tr>
<th>Isotope</th>
<th>$E_{\text{linear}}$ (keV)</th>
<th>$\beta/CE$ Emission probability (%)</th>
<th>Chip 1 (0.66 μL)</th>
<th>Chip 2* (1.46 μL)</th>
<th>PE10 (1.85 μL)</th>
<th>PE50 (7.93 μL)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>$\eta$ (cps/Bq)</td>
<td>$A_{\text{min}} - A_{\text{max}}$ (Bq/μL)</td>
<td>$\eta$ (cps/Bq)</td>
<td>$A_{\text{min}} - A_{\text{max}}$ (Bq/μL)</td>
</tr>
<tr>
<td>$^{64}$Cu</td>
<td>190, 278</td>
<td>37.2, 17.8</td>
<td>20%</td>
<td>100 – 5.0 $10^4$</td>
<td>20%</td>
<td>45 – 2.3 $10^4$</td>
</tr>
<tr>
<td>$^{18}$F</td>
<td>250</td>
<td>96.7</td>
<td>39%</td>
<td>51 – 2.5 $10^3$</td>
<td>39%</td>
<td>23 – 1.2 $10^3$</td>
</tr>
<tr>
<td>$^{11}$C</td>
<td>386</td>
<td>99.8</td>
<td>47%</td>
<td>42 – 2.1 $10^3$</td>
<td>47%</td>
<td>19 – 9.6 $10^4$</td>
</tr>
<tr>
<td>$^{68}$Ga</td>
<td>353, 836</td>
<td>1.2, 87.7</td>
<td>43%</td>
<td>47 – 2.3 $10^5$</td>
<td>43%</td>
<td>21 – 1.1 $10^5$</td>
</tr>
<tr>
<td>$^{99m}$Tc</td>
<td>120, 138</td>
<td>8.8%, 1%</td>
<td>4%</td>
<td>527 – 2.6 $10^6$</td>
<td>4%</td>
<td>238 – 1.2 $10^6$</td>
</tr>
</tbody>
</table>

* Estimated
Real Time Microfluidic Blood Counting System for PET and SPECT Preclinical Pharmacokinetic Studies

Laurence Convert, Réjean Lebel, Suzanne Gascon, Réjean Fontaine, Jean-François Pratte, Paul Charette, Vincent Aimez and Roger Lecomte

J Nucl Med.
Published online: May 5, 2016.
Doi: 10.2967/jnumed.115.162768

This article and updated information are available at:
http://jnm.snmjournals.org/content/early/2016/05/01/jnumed.115.162768

Information about reproducing figures, tables, or other portions of this article can be found online at:
http://jnm.snmjournals.org/site/misc/permission.xhtml

Information about subscriptions to JNM can be found at:
http://jnm.snmjournals.org/site/subscriptions/online.xhtml

JNM ahead of print articles have been peer reviewed and accepted for publication in JNM. They have not been copyedited, nor have they appeared in a print or online issue of the journal. Once the accepted manuscripts appear in the JNM ahead of print area, they will be prepared for print and online publication, which includes copyediting, typesetting, proofreading, and author review. This process may lead to differences between the accepted version of the manuscript and the final, published version.